Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature.

Ryu YS, Park SH, Kim JM, Kim EJ, Lee J, Kwok SK, Ju JH, Kim HY.

Rheumatol Int. 2012 Nov;32(11):3481-5. doi: 10.1007/s00296-011-2216-0. Epub 2011 Nov 8. Review.

PMID:
22065075
2.
3.

Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases.

Theibich A, Dreyer L, Magyari M, Locht H.

Clin Rheumatol. 2014 May;33(5):719-23. doi: 10.1007/s10067-013-2419-8. Epub 2013 Nov 8.

PMID:
24202614
4.

New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.

Matsumoto T, Nakamura I, Miura A, Momoyama G, Ito K.

Clin Rheumatol. 2013 Feb;32(2):271-5. doi: 10.1007/s10067-012-2113-2. Epub 2012 Nov 14. Review.

PMID:
23149905
5.

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.

Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13.

PMID:
22709496
6.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
7.

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP.

Ann Rheum Dis. 2013 Apr;72(4):517-24. doi: 10.1136/annrheumdis-2011-201244. Epub 2012 May 5. Review.

8.

Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.

Toussirot E, Berthelot JM, Pertuiset E, Bouvard B, Gaudin P, Wendling D, le Noach J, Lohse A, Lecuyer E, Cri L.

J Rheumatol. 2009 Nov;36(11):2421-7. doi: 10.3899/jrheum.090030. Epub 2009 Oct 1.

PMID:
19797509
9.

Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Komulainen R, Koivuniemi R, Yli-Kerttula U, Mali M, Sihvonen S, Krogerus ML, Jukka E, Nyrhinen S, Konttinen YT, Nordström DC.

Clin Rheumatol. 2011 Nov;30(11):1447-54. doi: 10.1007/s10067-011-1779-1. Epub 2011 Jun 7.

PMID:
21644062
10.

Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis.

Yang CT, Kuo CF, Luo SF, Yu KH.

Clin Rheumatol. 2012 Nov;31(11):1549-57. doi: 10.1007/s10067-012-2047-8. Epub 2012 Jul 31.

PMID:
22847245
12.

Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.

Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.

Isr Med Assoc J. 2008 Apr;10(4):277-81.

13.

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians.

Arthritis Rheum. 2009 May 15;61(5):560-8. doi: 10.1002/art.24463.

14.

[Neurological adverse events under anti-TNF alpha therapy].

Cohen M, Baldin B, Thomas P, Lebrun C.

Rev Neurol (Paris). 2012 Jan;168(1):33-9. doi: 10.1016/j.neurol.2011.06.005. Epub 2011 Nov 17. French.

PMID:
22098827
15.

Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis.

Mendonça JA, Marques-Neto JF, Samara AM, Appenzeller S.

Rheumatol Int. 2012 Mar;32(3):815-8. doi: 10.1007/s00296-011-1812-3. Epub 2011 Feb 15.

PMID:
21327431
17.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

18.

Problems encountered during anti-tumour necrosis factor therapy.

Desai SB, Furst DE.

Best Pract Res Clin Rheumatol. 2006 Aug;20(4):757-90. Review.

PMID:
16979537
19.

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

Arthritis Rheum. 2007 May;56(5):1417-23.

20.

Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab.

Diaz JC, Vallejo S, Cañas CA.

Rheumatol Int. 2012 Oct;32(10):3315-7. Epub 2011 Sep 1.

PMID:
21881980

Supplemental Content

Support Center